Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPARgamma)-specific agonist, as a modulator in experimental acute pancreatitis.
BACKGROUND
The purpose of this experiment was to investigate the role of PPAR ligands in the course of inflammation and of rosiglitazone, a PPAR-gamma-specific agonist, on the course of experimental acute pancreatitis (EAP).


METHODS
EAP was induced by administration of 5% sodium taurocholate injected into the pancreatic duct. The inflammatory activity was evaluated by biochemical scores (alpha-amylase, lipase, aminotransferases, and bilirubin), morphological changes (determined by light microscopy, H+E stained), and immunohistochemical reactions (ICAM, nitrotyrosine).


RESULTS
Rosilgitazone administered in the course of EAP at a dose 50 mg/kg p.o. decreased the intensity of morphological changes (edema, inflammatory infiltrates, necrosis, and erythrocyte extravasations). In the rosiglitazone-treated animals all the biochemical parameters of EAP were statistically significantly decreased. Immunohistochemical reactions against ICAM-1 and nitrotyrosine showed that rosiglitazone decreased the intensity of inflammatory reactions in the groups of treated animals.


CONCLUSIONS
PPAR-gamma agonists modulate the course of the inflammatory reaction. The administration of rosiglitazone decreased the intensity of the inflammatory process in the course of sodium taurocholate-induced EAP.
Celiński
Krzysztof
K
Department of Gastroenterology with Endoscopic Unit, Medical University, Lublin, Poland. celinski@mp.pl
Madro
Agnieszka
A
Prozorow-Król
Beata
B
Korolczuk
Agnieszka
A
Cichoz-Lach
Halina
H
Słomka
Maria
M
Korobowicz
Elzbieta
E
D000818:Animals; D001663:Bilirubin / Q000097:blood; D007150:Immunohistochemistry; D008049:Lipase / Q000097:blood; D047495:PPAR gamma / Q000819:agonists*; D019283:Pancreatitis, Acute Necrotizing / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D000077154:Rosiglitazone; D013656:Taurocholic Acid / Q000633:toxicity; D045162:Thiazolidinediones / Q000627:therapeutic use*; D000637:Transaminases / Q000097:blood; D000516:alpha-Amylases / Q000097:blood
D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D013656:Taurocholic Acid; D000637:Transaminases; D008049:Lipase; D000516:alpha-Amylases; D001663:Bilirubin